Pulmonary extracellular adenosine triphosphate in hypersensitivity pneumonitis and sarcoidosis : a preliminary study by Rosa, Beatriz Simões de Carvalho Rama
 Pulmonary extracellular adenosine triphosphate in hypersensitivity 
pneumonitis and sarcoidosis – a preliminary study 
 
 
Beatriz S. Rosa 
1,3
, Tiago M. Alfaro 
1,2,3
, Francisco Queiroz 
3
,
 
João Casalta-Lopes
4
, Rui 
Bártolo
5
, Ângelo R. Tomé 
3
, Rodrigo A. Cunha 
1,3
, Carlos Robalo-Cordeiro
1, 2
  
 
1 - Faculty of Medicine, University of Coimbra  
2 - Department of Pneumology, University Hospital Center of Coimbra,  
3 - CNC - Center for Neuroscience and Cell Biology, University of Coimbra,   
4 - Department of Biophysics, IBILI, Faculty of Medicine, University of Coimbra  
5 - Department of Clinical Pathology, University Hospital Center of Coimbra 
 
 
 
Address: 
Centro Hospitalar e Universitário de Coimbra,  
Serviço de Pneumologia, 2º andar 
Praceta Prof. Mota Pinto 
3000-075 – Coimbra 
Portugal 
E-mail: beatrizscrosa@gmail.com 
 
Pulmonary Extracellular Adenosine Triphosphate in Hypersensitivity 
Pneumonitis and Sarcoidosis 2012 
 
2   
 
 
Index: 
Abbreviation list ....................................................................................................................... 3 
Abstract  .................................................................................................................................... 4 
Resumo ...................................................................................................................................... 5 
Introduction .............................................................................................................................. 6 
Methods ..................................................................................................................................... 8 
Results ..................................................................................................................................... 12 
Tables and figures .................................................................................................................. 16 
Discussion  ............................................................................................................................... 20 
Acknowledgments / Agradecimentos: .................................................................................. 31 
References ............................................................................................................................... 27 
Supplementary data ............................................................................................................... 31 
 
 
 
 
  
Pulmonary Extracellular Adenosine Triphosphate in Hypersensitivity 
Pneumonitis and Sarcoidosis 2012 
 
3   
 
Abbreviation list 
 
ATP ............................................................................................... Adenosine triphosphate 
BAL ............................................................................................... Bronchoalveolar lavage 
BALF .................................................................................... Bronchoalveolar lavage fluid 
CF ................................................................................................................ Cystic Fibrosis 
COPD ................................................................... Chronic obstructive pulmonary disease 
CHUC .........................................................Centro Hospitalar e Universitário de Coimbra 
DLCO .................................................................................................... Diffusion capacity 
EBC ........................................................................................ Exhaled Breath Condensate 
FVC ................................................................................................... Forced vital capacity 
FEV1 ...................................................................... Forced expiratory volume in 1 second 
HP .........................................................................................Hypersensitivity pneumonitis 
ILDs .............................................................................................. Interstitial lung diseases 
IQR ....................................................................................................... Inter-quartile range 
IPF ......................................................................................... Idiopatic pulmonary fibrosis 
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Abstract  
Interstitial lung diseases comprise a vast and heterogeneous group of conditions that share 
clinical and radiological features, creating frequent difficulties in their differential diagnosis. 
Purinergic signaling has been shown to be involved in several lung diseases, including 
idiopathic pulmonary fibrosis, chronic obstructive lung disease, and cystic fibrosis. Our 
purpose was to compare the extracellular levels of adenosine triphosphate in several lung 
diseases to gauge its usefulness for differential diagnosis. We quantified the ATP 
concentration in the bronchoalveolar lavage fluid of 5 patients diagnosed with 
hypersensitivity pneumonitis, 8 patients with sarcoidosis and 10 with other lung diseases, 
using the luciferin-luciferase luminescence method. Clinical data were gathered from the 
patient’s clinical files, including pulmonary function tests. We found that the concentration of 
ATP was significantly lower in patients with hypersensitivity pneumonitis than in sarcoidosis. 
In fact, we observed that ATP was significantly correlated with total cells number and with 
diffusion capacity. This prompts the suggestion that the measurement of pulmonary 
extracellular ATP may assist in the differential diagnosis and warrens further studies to 
explore the signaling role of ATP in these diseases.  
 
 
Keywords: ATP, Hypersensitivity pneumonitis, Sarcoidosis, BALF  
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Resumo 
 
As doenças intersticiais pulmonares constituem um grupo vasto e heterogéneo de patologias 
que apresentam várias manifestações clínicas e imagiológicas em comum criando 
frequentemente dificuldades no seu diagnóstico diferencial. A sinalização purinérgica 
mostrou estar envolvida na patogénese de várias doenças pulmonares como a fibrose 
pulmonar idiopática, a doença pulmonar obstrutiva crónica e a fibrose quística. O objectivo 
deste estudo foi comparar os níveis de adenosina trifosfato em várias doenças pulmonares 
para avaliar a sua utilidade no diagnóstico diferencial. A concentração de ATP foi medida em 
lavados broncoalveolares de 5 doentes diagnosticados com pneumonite de hipersensibilidade, 
8 com sarcoidose e 10 com outras doenças pulmonares, utilizando o método de luminescência 
da luciferina-luciferase. Os dados clínicos dos pacientes foram obtidos dos processos clínicos, 
incluindo as provas de função pulmonar. A concentração de ATP no LBA de doentes com 
pneumonite de hipersensibilidade foi significativamente inferior aos doentes com sarcoidose. 
Adicionalmente foi verificada uma correlação da concentração de ATP com o número total de 
células e com a capacidade de difusão. Estes resultados lançam a sugestão que a medição de 
ATP poderá contribuir no diagnóstico diferencial alertando para a necessidade de realizar 
futuros estudos para explorar o papel da sinalização de ATP nestas patologias.  
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Introduction 
Interstitial lung diseases (ILDs) are a vast and heterogeneous group of pulmonary conditions 
that share clinical and radiological features, creating frequent difficulties in the differential 
diagnosis. (Kinder & Wells, 2009) Hypersensitivity pneumonitis (HP), also known as 
extrinsic allergic alveolitis, is an ILDs caused by intense and/or repeated inhalation of organic 
dusts and occupational antigens, with further sensitization. (Cordeiro et al, 2011; Girard et al, 
2009). On bronchoalveolar lavage fluid (BALF), HP shows the highest total cell and 
lymphocyte counts of all ILDs, with a proportion of lymphocytes usually exceeding 50%. It is 
a general belief that the CD4/CD8 T lymphocyte ratio is decreased; however, recent studies 
have demonstrated that this ratio may vary (Bonella et al, 2010). BALF findings are also 
dependent on the time span from the last antigen exposure; neutrophils are elevated within 48 
hours after acute exposure and return to normal within a week. When progression leads to 
pulmonary fibrosis, neutrophils may again be increasingly present in HP and the CD4/CD8 
ratio may show mild elevation. (Cordeiro et al 2007).  Pardo et al showed a positive 
correlation between the percentage of lung tissue polymorphonuclear leukocytes and the 
percentage of lung fibrosis in HP, but there was no correlation between BALF and lung 
neutrophils. (Pardo et al, 2000). 
Sarcoidosis is a multisystem granulomatous disorder of unknown cause (ATS/ERS/WASOG, 
1999). BALF shows lymphocytic alveolitis in 90% of patients at the time of diagnosis, 
independently of the stage of sarcoidosis and 55% show an increased CD4/CD8 ratio. Patients 
with active disease have a tendency to show a higher lymphocyte proportion and a 
particularly high CD4/CD8 ratio. In the last stage of sarcoidosis, neutrophils may also be 
elevated and some studies have demonstrated that an increased neutrophil count in BAL 
obtained from newly diagnosed patients with sarcoidosis, may indicate an unfavorable 
prognosis (Bonella et al, 2010). 
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Adenosine-5'-triphosphate (ATP) is considered a multifunctional molecule due to its several 
roles in metabolism, signaling and cell growth through the activation of P2 receptors (Bours 
et al, 2006). A role of purinergic regulation has been proposed in acute lung injury, 
mucociliary clearance, inflammation, wound healing, remodeling and lung fibrosis (Picher et 
al, 2011). In physiological situations, the extracellular concentration of ATP is kept at 
nanomolar concentrations through the activity of ectonucleotidases (Robson et al, 1997). 
Under conditions of cellular stress (such as exposure to bacterial endotoxin, reactive radicals 
or hypoxia), large amounts of ATP can be released into the pericellular space by many cell 
types, including epithelial and inflammatory lung cells and platelets. In vitro experiments 
have revealed that nucleotides act as chemoattractant for human neutrophils, eosinophils and 
dendritic cells and modulate the chemokine production and mucociliary clearance (Myrtek & 
Idzko, 2007).  
Bronchoalveolar lavage (BAL) is a minimally invasive technique, used for collection of 
samples from the peripheral airway, including cells, inhaled particles, infectious organisms 
and solutes (Bonella et al, 2010). Several previous studies have characterized BALF from 
patients with cystic fibrosis (CF) (Esther et al, 2008), asthma (Idzko et al, 2007; Lázár et al, 
2010), COPD (Lommatzsch et al, 2010) and idiophatic pulmonary fibrosis (IFP) (Riteau et 
al., 2010). In CF, the increased of ATP levels in BALF were correlated with neutrophil counts 
suggesting that extracellular purines are biomarkers of neutrophilic airway inflammation. In 
IFP, Ritteau et al (2010) identified extracellular ATP as a new danger signaling involving in 
the establishment of lung inflammation leading to fibrotic process.  
The objectives of our study were the evaluation of ATP concentrations in the BALF 
supernatant of patients with HP and sarcoidosis to decide on the interest of this quantification 
for the differential diagnosis between these disorders.  
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Methods  
Study Subjects 
Study subjects were recruited from the population of patients referred for bronchoscopy and 
bronchoalveolar lavage (BAL) at Centro Hospitalar e Universitário de Coimbra – Hospitais da 
Universidade de Coimbra (CHUC - HUC), during a nine months period (May 2011 to January 
2012), after approval by the local ethics committee. All exams were performed as clinically 
indicated by the patient’s physician. Only patients with a definite diagnosis at the time of ATP 
quantification (February 2012) were included in the analysis. The exclusion criteria were 
clinical or laboratory signs of infection, non-representative BALF and no definite diagnosis in 
February 2012. The diagnosis of sarcoidosis was performed according to WASOG criteria 
(ATS/ERS/WASOG, 1999) and the diagnosis of hypersensitivity pneumonitis was performed 
according to Richerson’s criteria (Richerson, 1989). Other patients (10) with lung cancer (2), 
pneumoconiosis (2), Wegener’s granulomatosis (2), polymyositis (1), eosinophilic pneumonia 
(1) and leukemia (2) were also included based on the relevant diagnosis criteria and the 
patient’s physician clinical diagnosis. For the purpose of this study, the patients were divided 
in three groups: sarcoidosis, hypersensitivity pneumonitis, and other diagnosis. 
 
 
Clinical data and lung function  
 
Clinical data were gathered from the patient’s clinical files stored at CHUC-HUC. We 
collected all the data required to fulfill the inclusion criteria, namely: blood urea 
quantification, radiological and lung function tests, smoking habits and therapy at the time of 
BALF collection (with systemic or inhaled steroids). Sarcoidosis patients were staged using 
the Scadding criteria on chest CT (stage 0: normal; stage I: bilateral hilar lymphadenopathy 
Pulmonary Extracellular Adenosine Triphosphate in Hypersensitivity 
Pneumonitis and Sarcoidosis 2012 
 
9   
 
(BHL), stage III: pulmonary infiltrations (without BHL); stage IV: pulmonary fibrosis) 
(Rajesh, 2004), an analysis carried out by a qualified radiologist as previously reported (Costa 
et al., 2012). Lung function tests (FVC, FEV1, DLCO-SB) were performed using 
Masterscreen PFT or Masterlab body, from Jaëger (calibrated daily) by certified respiratory 
technicians, and predicted values were calculated using published referential equations 
(Quanjer, 1993). All the information was maintained anonymous during the study. 
 
BALF collection and supernatant storage  
BALF collection: 
Briefly, bronchoscopy was performed with the patient in supine position and the 
bronchoscope was inserted through the nose or the mouth under local anesthesia with 
lidocaine. For BAL, the bronchoscope was wedged preferentially into a sub-segment of the 
right middle lobe and a total of 150 mL sterile 0.9% saline solution heated to 37ºC was 
instilled in three different 50 mL syringes. The BALF was recovered through gentle manual 
aspiration. After collection BALF was transported to the laboratory within two hours. 
Sample processing and storage:  
In the laboratory, BALF was filtered through sterile gauze to remove any visible particulate 
material and centrifuged at 380 g, during 10 minutes at 4°C. Approximately 1 mL of the 
supernatant was stored in adequately labeled Eppendorf 1.5 ml tubes. The samples were then 
stored at -20ºC, for a maximum of one month and then moved to -80ºC, until analysis.  Total 
and differential cell counting was performed as routinely done in the laboratory: For the 
quantification of the total cell count in BALF, a particle counter (LH780) was used. The 
differential cell count was performed on cytospin slides after staining with May-Grünwald-
Giemsa stain. Differential cell counts were made on a total count of at least 200 cells using 
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standard morphologic criteria. (Bonella et al, 2010). Lymphocyte subsets were determined by 
flow cytometry. Lymphocytes were stained by anti-CD3, anti-CD4, and anti-CD8 specific 
monoclonal antibodies for T lymphocytes and by anti-CD19 for B lymphocytes. (Zompi et al, 
2004) 
 
ATP quantification in BALF supernatants 
ATP quantification was performed using a Sigma ATP Bioluminescent Assay Kit (Sigma®), 
according to the manufacturer’s instructions. Briefly, 80 µL of BALF supernatant was added 
to 40 µL of recombinant luciferin-luciferase assay mix (Sigma®) in a new, sterile, white 
opaque 96 wells multiwell plate (Corning®). After one second of shaking, luminescence was 
detected over five seconds at a temperature of 25ºC. Both the addition and the luminescence 
analysis were performed by an automated multi-technology plate reader Wallac 1420 Victor 
3V (Perkin Elmer®, Sweden). Samples were measured in triplicate and the mean 
luminescence was used in the analysis. Standard curves of ATP in 0.9% saline solution were 
performed at the beginning and at the end of the experiment, and the mean values were used 
to create a standard curve. The samples under the detection limit of 1 x 10
-10.5
 mol/L of ATP 
were assigned to have an ATP concentration of this value. During the manipulation of the 
samples all efforts were made to maintain sterile conditions, including the use of sterile 
material and working in a flow chamber whenever possible.  In previous measurements we 
guaranteed data reproducibility between different days (data not shown). 
Dilution factor: urea measurement  
Urea was measured in BALF supernatant using a commercial quantitative colorimetric assay 
(QuantiChrom ®). The samples were prepared following the manufacturer introductions and 
the optical density was read at 430 nm after 50 minutes of incubation.  Using the value of 
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BALF urea and the serum urea obtained from the clinical files, we calculated the BALF 
dilution factor.   
Statistical analysis  
The statistical analysis was performed using IBM
®
 SPSS
®
 version 19. The sample 
characterization was done by calculating measures of location (median) and measures of 
spread (interquartile range) for quantitative variables and absolute and relative frequencies for 
qualitative variables. The normality test used was Shapiro-Wilk. The comparison of the total 
number of cells, neutrophils %, lymphocytes % and CD4/CD8 and pulmonary function 
(FVC%, FEV1%, DLCO%) between HP and sarcoidosis was performed using Mann-Whitney 
test. The comparisons of ATP quantifications between the HP and sarcoidosis patient groups 
were performed using Mann-Whitney test; when comparing the three groups Kruskal-Wallis 
test was used, with pairwise comparisons using Bonferroni correction. To assess the 
correlations between the ATP concentrations and the total cell counts, neutrophils, 
lymphocytes, CD4 and CD8 T lymphocyte numbers, these values were logarithmically 
transformed. Correlation between ATP concentration and lymphocyte, neutrophils and 
pulmonary function tests was performed using a Pearson correlation. To assess the correlation 
between CD4 or CD8 lymphocyte numbers and ATP concentrations we used a Spearman 
correlation test. The analysis of the differences between the time of BALF storage was 
performed by oneway ANOVA. All analyses were carried out establishing significance at 
95% confidence.  
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Results 
Patient population: 
Out of the 83 patients who performed BALF during this period, twenty three were included. 
The diagnosis were: sarcoidosis (8) HP (5) lung cancer (2), pneumoconiosis (2), Wegener’s 
granulomatosis (2), polymyositis (1), eosinophilic pneumonia (1) and leukemia (2). Subject’s 
demographics are detailed in Table I.  
None of the patients with sarcoidosis and HP was a current smoker or was under therapy with 
systemic or inhaled steroids, or thienopyridine class antiplatelet drugs. There was a positive 
smoking history in four patients with sarcoidosis and in five patients with other lung diseases’ 
group, all former smokers. None of the patients with a positive smoking history showed 
evidence of COPD. Of the eight patients with sarcoidosis, two had stage I (25%), five had 
stage II (62.5%) and one had stage III (12.5%). Two were diagnosed with Löfgren Syndrome.  
 
 
Differences of BALF characteristics and pulmonary function tests between HP and 
sarcoidosis group: 
 
Patients with HP had a higher percentage of lymphocytes than patients with sarcoidosis, 65 
(IQR 7) vs 9 (IQR 43) (p=0.04). HP patients also displayed a higher percentage of neutrophils 
18 (IQR 27) vs 1 (IQR 4) (p= 0.014), and the CD4/CD8 ratio was higher in sarcoidosis 
patient’s 3.17 (IQR 6.25) vs 0.95 (IQR 1.91) (p=0.042). No significant differences were found 
in the total cell count (p= 0.056) and in the percentage of eosinophils (p=0.2). BALF 
characteristics are show in table II and in figure 1. Regarding pulmonary function tests, which 
are detailed in table III and figure 2, FVC% was higher in sarcoidosis 98.1 (IQR 14.5) vs 76.7 
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(IQR 42.5) in HP; the same was observed in DLCO% (p=0.019), sarcoidosis 93.6 (IQR 29.1) 
vs HP 42.5 (IQR 39.1).  
 
Comparison of ATP concentrations in Sarcoidosis and HP groups: 
We next assessed the differences between ATP concentration in BALF supernatants of 
sarcoidosis and HP groups. We found that HP patients had a lower median ATP concentration 
in BALF 4x10
-11
 (IQR 4.5 x10
-10
) than sarcoidosis patients 1.64 x10
-9
 (IQR 6.67x10 
-9
) 
(p=0.019).    
Comparison of ATP concentrations between the three groups: 
We first performed a Kruskal-Wallis test that showed significant differences (p= 0.027) 
between the three groups. Pairwise comparisons demonstrated that the differences are due to 
the difference between HP group and the other two groups. The significance levels were: 
Sarcoidosis and PH (p=0.17), PH and others 1.72x10-9 (IQR 1.45x10
-9
) (p=0.013), 
Sarcoidosis and others (p=1.00). The differences between the three groups are illustrated in 
figure 3.   
 
Correlation of total and differential cell count composition and ATP concentration in BALF 
of HP and sarcoidosis patients 
There was a significant correlation between logATP concentration and the total number of 
cells(log) (Pearson correlation, R= -0.741, p=0.004). Due to the role of CD4 and CD8 T 
lymphocytes in the pathogenesis of sarcoidosis and HP we investigated their possible relation 
of ATP. For the purpose of this analysis, we only included HP and sarcoidosis groups and the 
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results were as follows: correlation of LogCD4 and LogATP in sarcoidosis patients 
(Spearman, R=-0.429, p=0.289); correlation of LogCD4 and LogATP in HP patients 
(Spearman, R=-0.41, p=0.493); correlation of LogCD8 and LogATP in sarcoidosis patients 
(Spearman, R=-0.333, p=0.42); correlation of LogCD8 and LogATP in PH patients 
(Spearman, R=-0.564, p=0.322); correlation of LogCD8 and LogATP in PH and sarcoidosis 
patients (Spearman, R=-0.757, p=0.003); correlation of LogCD4 and LogATP in PH and 
sarcoidosis patients (Spearman, R=-0.702, p=0.008).  
At the same we verified a correlation of the percentage of lymphocytes with Log ATP in PH 
and sarcoidosis (Pearson correlation R= -0.615, p=0.025); correlation of the number of 
lymphocytes(log) and LogATP in PH and sarcoidosis (Pearson correlation R= -0.803, p= 
0.001). In opposite there was no correlation with logneutrophils and logATP (Pearson 
correlation R= -0.676, p= 0.066).   
 
Possible correlation between ATP and pulmonary function in PH and sarcoidosis groups 
We next investigated the correlation of lung function tests (FVC%, FEV1%, DLCO%) and 
the concentrations of ATP in BALF. The only parameter that showed a significant correlation 
was DLCO percentage (Pearson correlation, R=0.581 p= 0.048). There was found no 
correlation in FVC% (Pearson correlation p= 0.158) and FEV1% (Pearson correlation 
p=0.093). 
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Comparison of the time of storage in the different groups 
As there have been reports of ATP degradation with time in frozen samples, to ensure that all 
sample had the same time of storage we tested for differences in the time of storage. We 
found no significant the differences between the three groups (p=0.325).  
 
Impact of the dilution factor in the ATP concentration 
The dilution factor of BALF varies between 2 and 134 in 14 samples evaluated.   
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Tables and images 
Table I- The table shows the patients demographics data: gender, smoking habits, mean and 
the standard deviation of patients’ age (years). 
Patient characteristics HP Sarcoidosis Others 
Subjects (n)  5 8 10 
Age (yr)  48 (13) 39.1 (8.7) 59 (14) 
Sex (male/female) 0/5 2 / 6 4/6 
Never smokers / ex-
smokers / current 
smoker 
5/0/0 4 /4/0 9/1/0 
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Table II- The table shows the median and interquartil range (IQR) of BALF characteristics: 
total cell count (10
6 
cells/uL), neutrophils, eosinophils, lymphocytes, CD4
+
 T lymphocytes, 
CD8
+
 T lymphocytes expressed in percentage (%) and CD4/CD8 ratio. 
BALF characteristics HP Sarcoidosis Others 
Total cell count (IQR)  320 (295) 100 (58) 80 (118) 
Neutrophils %  (IQR) 18 (27) 1 (4) 4 (7) 
Eosinophils % (IQR) 0 (1) 0   0 (8) 
Lymphocytes % 
(IQR) 
65 (47) 9 (43) 13 (15) 
CD4% (IQR) 40 (36.8) 69 (29.8) 62 (36.9) 
CD8 % (IQR) 30.2 (23) 22 (30.5) 21 (33.8) 
CD4 / CD8 (IQR) 0.95 (1.91) 3.17 (16.25) 2.3 (3.2) 
 
Table III-The table shows the  median and interquartil range (IQR) of the lung function tests  
of the three patient groups (FVC %, FEV1 %, DLCO %). 
Lung function tests HP Sarcoidosis Others  
FVC % (IQR) 84.3 (45.4) 97.3 (17.7) 111.9 (17.2) 
FEV1 % (IQR) 76.7 (42.5) 98.1(14.5) 107 (23.5) 
DLCO % (IQR) 42.5 (39.1) 93.6 (29.1) 91.5 (27.1) 
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Figure 1. BALF characteristics of the three groups, HP, sarcoidosis and other diseases, 
including total cells(10
6
 cells/L), neutrophils(%), lymphocytes(%), CD4(%) CD8(%) 
expressed by median. Patients with HP had higher Total cells count, lymphocytes(%), 
neutrophils(%) and CD8 T lymphocytes(%). In opposite, sarcoidosis patients showed a higher 
CD4 T lymphocyte (%). 
 
Figure 2. Lung function tests (FVC%, FEV1%, DLCO%) in HP, sarcoidosis and others 
groups.  FVC% and DLCO% are lower in HP than in sarcoidosis and others. 
0
50
100
150
200
250
300
350
Total cells
10^6/L
Neutrophils% Lymphocytes
%
CD4% CD8 %
HP
Sarcoidosis
Others
0
20
40
60
80
100
120
HP Sarcoidosis Others
FVC %
FEV1 %
DLCO%
Pulmonary Extracellular Adenosine Triphosphate in Hypersensitivity 
Pneumonitis and Sarcoidosis 2012 
 
19   
 
 
 
 
 
Figure 3. Comparison of ATP concentrations in BALF of the three groups (HP n=5, 
sarcoidosis n=8, others n=10). Significant differences were found between the three groups 
(p= 0.027). Two values of HP patients were below the detection limit of the technique. The 
vertical axis shows a logarithmic scale of ATP concentration. 
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Figure 4. Correlation of logATP (mol/L BALF) and log cells (10
6
) (p= 0.004) in sarcoidosis 
patiens (n=8) and HP patients (n=5) .  
 
Figure 5. Correlation of logATP (mol/L BALF) and DLCO% (p= 0.048) in sarcoidosis 
patiens (n=8) and HP patients (n=5).  
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Discussion  
The main finding of our study was a significant difference in extracellular ATP 
between sarcoidosis and HP, with HP patients displaying lower ATP concentrations in their 
BALFs. 
As it was expected, the percentage of lymphocytes and neutrophils was higher in HP 
than in sarcoidosis. In fact, in both cases, it is predictable that early-stage disease BALF 
presents a predominance of lymphocytes, whereas in the end-stage, including fibrosis, the 
percentage of neutrophils can rise substantially. Furthermore, the median of CD4/CD8 ratio 
was 3.17 in sarcoidosis, 0.95 in HP and 2.3 in other diseases. Actually, analyzing the 
observed differences between lung function tests, we could assess the impact of these diseases 
on the subjects.  FVC% and DLCO% are lower in HP than in sarcoidosis which can mean that 
there is a great impairment of function in HP patients compared to sarcoidosis group. 
Surprisingly, we observed significant differences in ATP concentrations between HP 
patients (in the order of 10
-11
 mol/L) and in sarcoidoisis (in the order of 10
-9
 mol/L). In fact, 
extracellular ATP in the BALF of sarcoidosis patients has been described in a previous study 
by Lommatzsch et al. (2010), where no differences were found in concentrations of 
sarcoidosis patients and the healthy control group, leading the authors to conclude that 
sarcoidosis patients had normal ATP levels in BALF. This study included a sarcoidosis group 
in order to show that it is unlikely that the increase in ATP concentrations found in COPD 
patients reflects elevated cell numbers in BALF (Lommatzsch et al., 2010) Despite the 
differences in methodology, and considering the lack of a dilution analysis, we quantified 
levels of ATP in the BALF of patients with sarcoidosis (1.64 x10
-9 
mol/L) that are similar to 
these described by the authors (  15 nmol/ml).  
Pulmonary Extracellular Adenosine Triphosphate in Hypersensitivity 
Pneumonitis and Sarcoidosis 2012 
 
22   
 
Our results also show a clear negative correlation between ATP concentration in both 
groups with the total cells in BALF. Although similar correlations were found with the 
differential cells percentage (lymphocytes), this needs to be carefully interpreted and 
integrated with the pathophysiology of the diseases, and larger studies are essential to 
understand the impact of each cell type in this correlation. Furthermore, the positive 
correlation of ATP with DLCO, suggests a possible inverse correlation between extracellular 
ATP concentration and the impairment of lung function.   
Despite the significant correlation found between CD4 cell count and ATP levels and 
CD8 cell count and ATP levels when we analyzed in the two groups together, the lack of the 
same correlation in HP and sarcoidosis separately, is strongly limited by the size of cohort (5 
and 8, respectively). 
There are two hypotheses to understand ATP concentrations in BALF. On the one 
hand, purine concentrations in BALF may be overestimated because BALF is collected 
invasively and the mechanical and osmotic forces generated during lavage may trigger ATP 
release by airway epithelial (induced by bronchial washing), or cellular ATP leakage. On the 
other hand, measured ATP concentrations are probably underestimated because of rapid ATP 
degradation in biological fluids and because of the dilution of the liquid covering alveolar 
epithelium during the lavage. Enzymatic ATP degradation may also occur during sample 
processing. ATP concentrations in the close vicinity of cells are probably higher than 
measured, and are thus able to reach concentrations required for purinergic receptor 
activation. (Riteau et al, 2010). In fact, we cannot also exclude the possibility of ATP may 
have been degraded during storage and sample handling, despite our best care to prevent this 
during manipulation. However, all samples were similarly manipulated, namely with a similar 
storage period, as shown in the results.  
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For this study it was important to assure that the differences in ATP concentrations 
were not influenced by the smoking history of the patients, and natural course of the diseases 
by the use of systemic or inhaled therapy. The exclusion of patients with an acute infection 
eliminates another potential source of extracellular purines, bacteria, although inflamed 
airway epithelia can be significant contribution from other inflammatory cells.  
Despite our initial plan to control the dilution of BALF samples using the urea assay, 
we faced practical problems and this could not be performed in all samples. We chose urea 
because of its small molecular weight, and because urea reaches complete equilibrium across 
the capillary-alveolar membrane, allowing us to calculate a serum urea to BALF urea ratio 
(Rennard et al. 1986). The ERS guidelines for the measurement of acellular components and 
standardization of BAL states that urea is widely used as an internal marker, but this report 
reviews evidence showing that urea has several limitations for use as an internal marker of 
dilution since it continues to pass rapidly from the blood and tissue spaces into the newly 
instilled lavage fluid (Haslam & Baughman, 1999). Regarding the problem of the unknown 
BAL dilution, the Task Force concludes that there is still no method to accurately determine 
the dilution factor and recommends efforts for the reduction of the variability of the procedure 
and analysis. However, the 14 samples analyzed suggest that our results were consistent with 
those previously reported 2- 134 (10–100-fold).  
In this study, to measure the ATP concentration we used a very sensitive luminescent 
technique able to detect very low ATP concentration. Because of ATP’s unique chemical 
properties, other techniques, as chromatography/mass spectrometry, cannot be easily used. 
(Làzar et al, 2010). We ruled out possible interactions with BALF constituents with kinetics 
analysis of luciferase, we tested the presence of ATP with apyrase and daily reproducibility 
was guaranteed (data not shown). In fact, HP concentrations were very closely to the 
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detection limit (2 inferior) but this fact doesn’t interfere in our results and the differences may 
be even higher. 
Our results could suggest two alternative possibilities to understand the different levels 
of ATP in HP and sarcoidosis: One possibility is that the ATP concentrations are related with 
the pathogenesis of these diseases and may reflect the differences in purinergic signaling in 
both diseases. The other possibility if that the differences result from a different extracellular 
catabolism of ATP. These differences could be due to the total cells count or to differences in 
BALF constituents (different types of ectonucleotidases profile in each disease). In fact, if the 
differences found between sarcoidosis and HP are confirmed a large scale study, extracellular 
ATP can have a possible role in the different diagnosis of these disorders, particularly if the 
same results can be transported to exhaled breath condensate (EBC), although this would 
probably require a technique of improved sensitivity and lower detection limit. This could 
actually give us an indirect evaluation of total cells counts in the lung parenchyma. EBC has 
been used as a non-invasive method to assess airway purine concentrations. The advantage of 
this method is that it only requires the subject to breathe normally through a chilled tube, 
which does not introduce osmotic or mechanical forces that may compromise purine 
concentrations (Esther et al, 2011).  
In spite of the tentative conclusions derived from the present study, it would be 
advisable to replicate the present findings in a larger cohort of patients with sarcoidosis and 
HP, including patients with an advanced stage of fibrosis, as extracellular ATP is a danger 
signal and is involved in the establishment of lung fibrosis (Riteau, 2010). Recently, a new 
therapeutical target for IPF was proposed, the P2X7 receptor for which inhibitors where 
shown to be effective in animal models of neurological diseases. (Riteau, 2010) 
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Also to complement this study, additional definition of the profile of the activity of 
ectoendonucleotidases in BALF from patients with each disease and their correlation with 
BALF constituents would be of interest, specially the study of CD4 and CD8 T lymphocytes.  
We also tried an initial approach to the study of eosinophilic diseases as eosinophils are also 
related with purinergic signaling. In fact, in a patient with eosinophilic leukemia (total cells 
1890x10
6
/L), we found the third lowest value of ATP. At the same time, it also could be 
interesting extending to certain types of tumors like leukemia and lymphoma.     
Our study has some limitations. First, the small size of this cohort limits the statistical 
power of the comparisons and correlations attempted. Additionally, the collection of clinical 
information and diagnoses in a retrospective manner always limits the strength of the 
proposed conclusions. Finally, it is worth noting that the present study did not include a 
formal control group. In fact, BALF are not usually performed on healthy subjects, thus 
hampering the availability of this relevant group of individuals. To overcome this limitation, 
we included a third group of patients with different other lung diseases that mostly have an 
increase in the percentage and number of lymphocytes serving as a control group.  
In conclusion, the present study suggests that the pulmonary extracellular ATP 
concentrations in BALF of patients with HP is lower than in patients with sarcoidosis and this 
could be related with the total cell count in BALF. It should be noted that the strength of these 
conclusions are limited by the size of the cohort of BALF samples analyzed, the design of the 
study as a retrospective collection of information and the limitations inherent to the 
methodology. It is hoped that future prospective studies carried out in a larger number of 
patients with hypersensitivity pneumonitis and sarcoidosis may confirm the presently 
proposed conclusions, as well as elucidate about possible correlation with the differential cell 
proportion. This conclusion raises the possibility for a role of the evaluation of pulmonary 
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extracellular ATP in the differential diagnosis of these diseases and a significant role of the 
purinergic signalling pathways in these diseases.  
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Supplementary data 
 
Table IV- List of cases with information on age, gender, BAL date, Sarcoidosis stage by 
Chest CT, Smoking habits, High Blood Pressure (HBP) and Therapeutics.  
HP- Hypersensitivity pneumonitis, S- sarcoidosis, LT- Lung Tumor, Pnc – pneumoconiosis, 
WG- Wegener Granulomatosis, Pm – Polimiositis, EPn – eosinophilic pneumonia, EL – 
Eosinophilic Leukemia, CLLB – Chronic Lymphoid Leukemia B, F- female, M – male, NS – 
never smoker, Ex – Ex smoker, PY -  Pack years,  NSS – No systemic steroids  
Cases Age, yrs Gender BAL Date Stage 
Chest CT 
Smoking 
Habits 
HBP, Therapeutics 
HP1 58 F 09/08/11  NS HBP, NSS 
HP2 31 F 16/08/11  NS NSS 
HP3 57 F 30/05/11  NS NSS 
HP4 37 F 26/05/11  NS Atorvastatin, NSS 
HP5 57 F 18/07/11  NS Simvastatin, NSS 
S1 36 F 01/08/11 II Ex 15 PY NSS 
S2 52 F 08/08/11 III Ex 25 PY Steroids history 
S3 41 M 16/08/11 II NS NSS 
S4 40 F 26/09/11 II Lofgren Ex NSS 
S5 36 F 19/09/11 II NS NSS 
S6 35 F 06/12/11 II Lofgren NS NSS 
S7 49 F 19/10/11 I NS Atorvastatin, NSS 
S8 24 M 24/11/11 I Ex 5 PY  
LT1 59 M 06/12/11  Ex 100  
LT2 55 F 06/09/11  NS  
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Pnc1 52 F 08/11/11  NS NSS 
Pnc2 56 M 08/11/11  NS HBP, NSS 
GW 38 F 20/06/11  NS NSS 
GW 70 F 08/09/11  NS HBP, Symbicort® 
Pm 52 F 18/07/11   Methylprednisolone 
EPn 82 M 07/07/11  NS HBP 
EL 47 M 23/08/11   Prednisolone 
CLLB 
79 F 
15/06/11 
 
NS 
HBP, 
Methylprednisolone 
 
 
Table V –Lung Function in different patients.  FVC -  Forced Vital Capacity, FEV1 %, 
FEV1/FVC, DLCO,  
 
Cases FCV% FEV1% DLCO 
HP1 59.8 61.4 24.5 
HP2 43.8 48.6 37.4 
HP3 88.1 84.7 42.5 
HP4 84.3 76.7 51.2 
HP5 106.3 110.3 89 
S1 91.63 91.7 86.2 
S2 108,8 109,5 85,8 
S3 91.08 95.04 117.7 
S4 135.5 132.8 114.9 
S5 89.5 92.6 81.8 
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S6    
S7 97.3 98.1 93.6 
S8 98.1 103.5 95 
T1    
T2    
Pnc1 107.78 104.35 86.5 
Pnc2 116.34 125.43 113.9 
UG 111.9 107 91.5 
UG 127.43 121.74 112.8 
Pm 101.5 95.9 86.1 
Pne    
EL    
CLLB    
 
 
Table VI– BALF cellular characteristics 
Cases Cells/ 
uL 
Neutrophils % Eosinophils% Lymphocytes% CD4/CD8 
HP1 450 39 0 20 3.04 
HP2 170 2 0 65 2.07 
HP3 320 18 0 65 0.7 
HP4 360 6 2 73 0.95 
HP5 50 22 0 25 0.58 
S1 120 3 0 5 3.05 
S2 90 0 0 1 0.78 
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S3 70 4 0 18 2.21 
S4 60 0 0 6 3.29 
S5 40 5 0 12 1.33 
S6 120 2 0 69 31 
S7 120 0 0 55 22 
S8 110 0 0 2 5.2 
T1 60 2 0 24 0.58 
T2 90 4 0 27 2.1 
Pnc1 70 8 0 14 3,.8 
Pnc2 160 3 0 4 0.89 
UG 30 4 2 12 2.54 
UG 40 9 0 22 4.22 
Pm 180 6 0 40 0.56 
Pne 50 16 27 10 8.75 
EL 1890 0 74 8 1.33 
CLLB 140 1 0 10 3.94 
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Table VII– ATP concentrations in BALF of the diferente patients. 
Cases ATP mol/L 
HP1 3,16 x10-11* 
HP2 4,08611E-10 
HP3 3,16 x10-11* 
HP4 4,36E-11 
HP5 5,66003E-10 
S1 5,60264E-09 
S2 7,77911E-09 
S3 1,58347E-10 
S4 1,63587E-09 
S5 1,26614E-08 
S6 2,06174E-10 
S7 1,66397E-09 
S8 1,61E-09 
T1 1,74681E-09 
T2 2,49E-09 
Pnc1 1,57341E-09 
Pnc2 1,69796E-09 
UG 7,49135E-09 
UG 3,06459E-09 
Pm 3,25223E-10 
Pne 1,46324E-09 
EL 3,60246E-11 
CLLB 2,22104E-09 
*inferior detection limit 
